DBV Technologies (NASDAQ:DBVT) Issues Quarterly Earnings Results

DBV Technologies (NASDAQ:DBVT) posted its earnings results on Wednesday. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.44), FiscalAI reports. The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $0.56 million. DBV Technologies had a negative return on equity of 115.81% and a negative net margin of 5,392.17%.

Here are the key takeaways from DBV Technologies’ conference call:

• DBV submitted its BLA for the VIASKIN Peanut patch in children ages 4–7 and expects to pursue priority review based on the product’s breakthrough therapy designation.
• Fareva Amboise continues remediation following an FDA warning letter related to site-wide quality systems. DBV said progress is on track and that its February 1, 2027 PAI-readiness target provides a buffer, but the FDA reinspection has not yet been scheduled.
• DBV plans to submit a separate BLA for toddlers ages 1–3 in 2027, using a sequential review strategy intended to avoid an FDA bottleneck and leverage learnings from the 4–7 review.
• Cash and cash equivalents totaled $165.7 million, supporting operations into the third quarter of 2027, but operating expenses rose to $164.4 million as the company funded regulatory development and commercial-launch preparations.
• The company is building commercial infrastructure, including plans for a 50–70-person U.S. sales force targeting approximately 4,500 allergists, payer engagement, marketing, and pre-commercial inventory; however, DBV declined to provide first-year sales guidance.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $10.29 on Friday. The firm has a market capitalization of $647.01 million, a price-to-earnings ratio of -3.42 and a beta of -1.04. DBV Technologies has a one year low of $8.63 and a one year high of $26.18. The business has a fifty day moving average price of $11.62 and a 200-day moving average price of $16.97.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DBVT. Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a research report on Thursday, October 15th. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Citigroup restated a “market outperform” rating on shares of DBV Technologies in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research report on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of DBV Technologies in a research note on Thursday, September 10th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $46.50.

DBV Technologies Company Profile

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.